EMERYVILLE, CALIFORNIA, April 29, 2026
Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to develop AI-designed site-specific recombinases aimed at advancing next-generation genetic medicines. The partnership combines Profluent’s frontier AI foundation models for protein design with Lilly’s expertise in clinical development and commercialization of genetic therapies, with the goal of enabling precise, large-scale DNA editing capabilities. The agreement includes upfront payments, research funding, and up to $2.25 billion in milestone-based compensation, reflecting the significant potential of this technology to transform treatment approaches for diseases with severe unmet medical needs.
AI-Designed Recombinases Enable Precision Gene Editing
At the core of the collaboration is the development of custom-designed recombinases, a class of enzymes capable of targeting and modifying DNA at precise genomic locations. Unlike traditional gene editing tools that rely on naturally occurring enzymes with limited flexibility, Profluent is leveraging artificial intelligence to design entirely new proteins tailored for specific genomic targets.
This approach aims to overcome one of the biggest challenges in genetic medicine: kilobase-scale DNA editing, which involves inserting or modifying large segments of DNA, including entire genes. Such capabilities are essential for treating complex genetic diseases caused by multiple mutations, where conventional editing technologies often fall short. By enabling programmable and scalable genome editing, the collaboration represents a major leap forward in precision medicine and synthetic biology.
Expanding Therapeutic Reach Across Complex Diseases
Advertisement
Many genetic disorders involve heterogeneous mutations across patient populations, making it difficult to develop therapies that work universally. The ability to perform large-scale, precise DNA insertions could allow scientists to correct entire gene sequences rather than individual mutations, dramatically expanding the scope of treatable conditions. Through this partnership, Profluent will apply its AI-driven protein design platform, trained on one of the largest datasets of natural recombinases, to generate optimized enzymes for multiple therapeutic targets.
Lilly will receive exclusive rights to advance selected recombinases through in vivo studies, preclinical development, and clinical trials, ultimately leading to commercialization. This integrated approach highlights the growing importance of AI in drug discovery and genetic engineering, particularly in tackling diseases that have remained historically difficult or impossible to treat.
Strategic Collaboration Signals Future of AI-Driven Biopharma
The Profluent–Lilly partnership reflects a broader shift in the biopharmaceutical industry toward AI-enabled innovation and strategic collaborations. By combining computational biology with pharmaceutical development expertise, the companies aim to accelerate the translation of cutting-edge research into clinical applications.
From a GxP perspective, the program will require rigorous adherence to Good Laboratory Practice (GLP) during early research, followed by Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) as therapies progress toward commercialization. The collaboration also underscores the increasing role of AI-designed biologics in shaping the future of medicine, offering the potential to create fully programmable therapeutic platforms applicable to both rare and common diseases. As demand for precision genetic therapies continues to grow, this partnership positions both companies at the forefront of a new era in gene editing and personalized medicine, with the potential to unlock treatments that were previously considered beyond reach.
Source: Profluent, Eli Lilly press release
